- The inherited retinal diseases market is witnessing substantial growth, primarily driven by increasing awareness, advancements in genetic diagnostics, and the growing need for targeted therapies to treat rare retinal disorders. Innovations in gene therapy and retinal implants are further accelerating market expansion by offering hope to patients with previously untreatable genetic vision conditions
- The growing emphasis on personalized medicine and advancements in genomic technologies is increasing the demand for accurate and early diagnosis of IRDs. Tools such as next-generation sequencing (NGS), CRISPR gene editing, and adeno-associated virus (AAV)-based gene delivery systems are contributing significantly to the development of novel treatment approaches tailored to individual genetic profiles
- North America dominated the global inherited retinal diseases market, with the largest revenue share of 38.9% in 2024. This leadership is due to the region’s strong healthcare infrastructure, high prevalence of retinal diseases, robust R&D funding, and the presence of key players actively engaged in gene therapy trials
- Asia-Pacific is projected to be the fastest-growing region in the global inherited retinal diseases market during the forecast period (2025–2032), driven by increasing investments in healthcare infrastructure, growing awareness of genetic eye disorders, improved access to genetic testing, and the emergence of research collaborations in countries such as China, India, and Japan
- Retinitis Pigmentosa dominated the disease type segment, with a market share of 41.2% share in 2024. Its high prevalence among inherited retinal conditions, coupled with focused research efforts and targeted gene therapies, makes it the most extensively studied and treated IRD subtype, driving its leading position in the market
